Plain-English translation of NCT07660055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called , which uses a radioactive substance to target and treat advanced cancers. The trial has two parts: first, doctors will test different doses to find the safest and most effective amount, and then they will study how well the medication works at that dose. Participants will receive imaging scans before treatment to help doctors see if the cancer is the right type for this medication.
Many patients with advanced breast, lung, gastric, and bladder cancers stop responding to standard treatments, and new options are urgently needed. This medication uses radioactive technology in a new way to directly attack cancer cells, offering hope for patients who have exhausted other treatment options.
You likely qualify if…
You likely don't qualify if…
You will have an imaging scan (PET/CT or PET/MRI) using a special tracer to see if your cancer is the right type for this treatment. If eligible, you will then receive the new radioactive medication, with the dose potentially increasing as the trial progresses through its first phase. You will have regular follow-up visits and scans to monitor how your body tolerates the treatment and whether your cancer responds, with safety monitoring continuing after your treatment ends.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Australia
Canada
Japan